Gentex Growth Story Offset by Margin and China Pressures, Wait Rating Maintained

What happened

Gentex's advanced automotive technologies and new program wins continue to drive revenue growth, but rising material costs and margin pressure are eroding profitability. China weakness, driven by tariffs and counter-tariffs, remains a significant drag, with Q4 2025 China sales down 33% year-over-year to approximately $34.5 million. The VOXX acquisition, while boosting top-line, has a structurally lower gross margin (29.7% vs core 34.7%) and has yet to demonstrate the promised ~$40 million annual cash flow synergies. Management guides 2026 revenue of $2.60-$2.70 billion with gross margin of 34%-35%, but tariff and commodity headwinds of $45-$50 million threaten the margin floor. Given the balanced risk/reward, the stock currently trades near fair value, and we maintain a WAIT rating until margin stability and VOXX integration progress are confirmed.

Implication

The current valuation at ~14x earnings and ~11.5x EV/EBITDA prices in stable mid-34% gross margins and a successful VOXX integration, which are not yet assured. The next two quarterly reports will be critical: if gross margin falls below 34% or China sales step down further, the stock could retest the $22 attractive entry level. Conversely, if margin holds and VOXX cost actions materialize, the stock has room to appreciate toward the $26-$30 range. Given the discretionary nature of buybacks and capacity expansions, capital returns may slow if cash flow weakens, removing a key support for the stock. Patient investors should wait for concrete evidence of margin durability before initiating or adding to positions.

Thesis delta

The core thesis remains unchanged: Gentex needs to prove it can sustain 34%+ gross margins despite tariff and commodity headwinds while converting VOXX into a cash flow contributor. The new article reinforces existing concerns about margin pressure and China weakness without providing new data that would alter our WAIT rating. Confidence in the current thesis is moderate, pending Q1-Q2 2026 results.